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Introduction
Phthalates are high-production   chemicals 
widely used in consumer products 
(Sathyanarayana 2008). Exposures are ubiqui-
tous, including among inner-city populations 
[Centers for Disease Control and Prevention 
(CDC) 2009; Whyatt et al. 2012]. Diet is 
thought to be the main source of exposure for 
di(2-ethylhexyl) phthalate (DEHP), although 
nondietary pathways also can be substantial 
for other phthalates (Carlstedt et al. 2013; 
Koch 2013). Phthalates have short biologic 
half-lives, with most metabolites eliminated 
within 24 hr (Wittassek and Angerer 2008). 
Measures of phthalate metabolites in the 
urine are informative as internal dosimeters of 
exposure because urinary enzymatic activity is 
negligible (Kato et al. 2004). Thus, metabolite 
concentrations in urine reflect an individual’s 
internal exposure to phthalates, rather than 
phthalate contaminants introduced into their 
urine sample during collection and processing. 
Prior studies have shown moderate intra-
class correlation coefficients (ICCs) for most 
phthalate metabolites in repeat urine samples 
indicating reasonable reliability (Hauser 
et al. 2004; Teitelbaum et al. 2008; Whyatt 
et al. 2012).
Preliminary epidemiologic findings 
suggest that phthalates may be associated with 
child asthma and other respiratory problems 
(Bornehag and Nanberg 2010; Kwak et al. 
2009). Among Swedish children 3–8 years 
of age, house dust concentrations of DEHP 
were associated with physician-confirmed 
asthma, and concentrations of butylbenzyl 
phthalate (BBzP) were associated with child 
eczema and rhinitis (Bornehag et al. 2004). 
A follow-up study from Bulgaria reported 
that house dust DEHP concentrations were 
associated with child asthma (Kolarik et al. 
2008). In cross-sectional analyses, urinary 
concentrations of diethyl phthalate (DEP) and 
di-n-butyl phthalate (DnBP) metabolites were 
associated with decreased forced expiratory 
volume in 1 sec (FEV1) in adult males but 
not adult females (Hoppin et al. 2004). We 
previously reported a statistically significant 
association between fractional exhaled nitric 
oxide (FeNO), a measure of airway inflam-
mation, and concentrations of metabolites 
of DEP and BBzP, in urine collected from 
cohort children at 5–9 years of age (Just et al. 
2012a). In addition, two studies have shown 
that polyvinyl chloride (PVC) materials in the 
home, exposure sources for BBzP and DEHP, 
are associated with child asthma and other 
respiratory symptoms (Bornehag and Nanberg 
2010; Larsson et al. 2010).
Increasingly, it is becoming evident that 
the prenatal period is an important window 
of susceptibility when environmental expo-
sures may affect lung development and respi-
ratory health (Duijts 2012; Miller et al. 2001; 
Rosa et al. 2011). However, to our knowl-
edge no prior studies have been published 
on effects of prenatal phthalate exposures 
and child asthma. The current study was 
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Background: Studies suggest that phthalate exposures may adversely affect child 
respiratory health.
oBjectives: We evaluated associations between asthma diagnosed in children between 5 and 
11 years of age and prenatal exposures to butylbenzyl phthalate (BBzP), di-n-butyl phthalate 
(DnBP), di(2-ethylhexyl) phthalate (DEHP), and diethyl phthalate (DEP).
Methods: Phthalate metabolites were measured in spot urine collected from 300 pregnant inner-
city women. Children were examined by an allergist or pulmonologist based on the first parental 
report of wheeze, other respiratory symptoms, and/or use of asthma rescue/controller medication 
in the preceding 12 months on repeat follow-up questionnaires. Standardized diagnostic criteria 
were used to classify these children as either having or not having current asthma at the time of the 
physician examination. Children without any report of wheeze or the other asthma-like symptoms 
were classified as nonasthmatics at the time of the last negative questionnaire. Modified Poisson 
regression analyses were used to estimate relative risks (RR) controlling for specific gravity and 
potential confounders.
results: Of 300 children, 154 (51%) were examined by a physician because of reports of wheeze, 
other asthma-like symptoms, and/or medication use; 94 were diagnosed with current asthma and 
60 without current asthma. The remaining 146 children were classified as nonasthmatic. Compared 
with levels in nonasthmatics, prenatal metabolites of BBzP and DnBP were associated with a 
history of asthma-like symptoms (p < 0.05) and with the diagnosis of current asthma: RR = 1.17 
(95% CI: 1.01, 1.35) and RR = 1.25 (95% CI: 1.04, 1.51) per natural log-unit increase, respec-
tively. Risk of current asthma was > 70% higher among children with maternal prenatal BBzP and 
DnBP metabolite concentrations in the third versus the first tertile.
conclusion: Prenatal exposure to BBzP and DnBP may increase the risk of asthma among inner-
city children. However, because this is the first such finding, results require replication.
citation: Whyatt RM, Perzanowski MS, Just AC, Rundle AG, Donohue KM, Calafat AM, 
Hoepner LA, Perera FP, Miller RL. 2014. Asthma in inner-city children at 5–11 years of age and 
prenatal exposure to phthalates: the Columbia Center for Children’s Environmental Health Cohort. 
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designed to fill this gap. We hypothesized 
that maternal prenatal urinary metabolite 
concentrations of BBzP, DnBP, DEHP, and 
DEP would be associated with current asthma 
among inner-city children.
Methods
The study includes 300 inner-city women 
and their children, 5–11 years of age, partici-
pating in the Columbia Center for Children’s 
Environmental Health (CCCEH) longitudinal 
birth cohort of 727 women enrolled between 
1998 and 2006 while they were pregnant 
with the index child. Women 18–35 years 
old, who self-identified as African American 
or Dominican and had resided in northern 
Manhattan or the South Bronx for at least 
1 year before pregnancy, were enrolled through 
prenatal clinics at Harlem and New York 
Presbyterian Hospital (Perera et al. 2003). 
Women were excluded from enrollment into 
the cohort if they reported active smoking, 
used other tobacco products or illicit drugs, 
had diabetes, hypertension, or known HIV, 
or had their first prenatal visit after 20 weeks 
gestation. The 300 children were included 
in the present analysis if phthalate metabo-
lite concentrations had been measured in a 
maternal spot urine sample collected during 
pregnancy and data were available for model 
covariates and to classify the child’s asthma 
status. Children were excluded from the 
present analysis if their mothers reported 
active smoking during pregnancy (n = 30), if 
prenatal maternal urine phthalate metabolite 
concentrations were not available (n = 281), 
if children were lost to follow-up (n = 89), or 
were missing covariate data (n = 27). The 300 
children were similar to the other children in 
the CCCEH cohort with regard to their race/
ethnicity, maternal prenatal marital status and 
education level, household income, household 
tobacco smoke exposure, maternal asthma, or 
maternal demoralization during pregnancy (see 
Supplemental Material, Table S1). All women 
signed an IRB-approved consent form and 
children signed an IRB-approved assent form 
beginning at age 7. The institutional review 
boards at the Columbia University Medical 
Center and the CDC approved the study.
Urine sample collection and phthalate 
measurements. A spot urine sample was 
collected from the women (n = 300) during 
the third trimester (mean ± SD, 34.0 ± 3.0 
weeks gestation; median, 33.7 weeks) and from 
the children at ages 3 (n = 216), 5 (n = 270) 
and 7 years (n = 154). Samples were analyzed 
for the following four phthalate metabolites at 
the CDC using solid phase extraction coupled 
with high performance liquid chromatog-
raphy–isotope dilution tandem spectrometry 
as described (Kato et al. 2005): mono(2-ethyl-
5-hydroxyhexyl) phthalate (MEHHP), as a 
representative of the DEHP metabolites as 
described (Just et al. 2012a); monobenzyl 
phthalate (MBzP), a metabolite of BBzP; 
mono-n-butyl phthalate (MnBP), a metabolite 
of DnBP; and monoethyl phthalate (MEP), 
a metabolite of DEP. Bisphenol A (BPA) was 
measured in maternal and child urine samples 
using solid phase extraction coupled with high 
performance liquid chromatography-isotope 
tandem mass spectrometry (Ye et al. 2005). 
Specific gravity was measured in the urine 
samples using a handheld refractometer and 
was used to control for urinary dilution (Atago 
PAL 10-S; Bellevue, WA) (Hauser et al. 2004).
Diagnosis of child asthma. At child ages 
5, 6, 7, 9, and 11 years, repeat question-
naires were administered to the mother or 
guardian to gather information on asthma-
like symptoms in the child. The questionnaires 
were administered in English or Spanish 
by fully bilingual research workers. These 
included the well-validated International 
Study of Asthma and Allergies in Childhood 
(ISAAC) questionnaire (Asher et al. 1995) 
and the Brief Respiratory Questionnaire 
(BRQ) (Bonner et al. 2006), as well as report 
of asthma rescue and/or controller medica-
tion. As described previously (Donohue et al. 
2013), children were referred for physician 
evaluation for asthma based on the first report 
that the child had wheeze or whistling in the 
chest, a cough that lasted more than a week, 
other breathing problems, and/or use of 
asthma rescue or controller medication in the 
preceding 12 months on any of the follow-up 
study questionnaires. Examinations included 
a standardized history, physical examination, 
and prebronchodilator and postbronchodilator 
pulmonary function testing. Two allergists/
pulmonologists independently reviewed the 
results of each examination and classified their 
asthma status according to the following pre-
specified criteria: a) current asthma symptoms 
OR current asthma medication AND either 
a 12% increase in FEV1 or a 30% increase 
in FEF25–75 postbronchodilator; b) current 
asthma symptoms OR current asthma medica-
tion AND history of asthma symptoms on 
previous questionnaires; c) history of asthma 
symptoms on previous   questionnaires AND 
wheeze on current exam.
The physician examination was conducted 
once during study follow-up, and the children 
were classified as having current asthma or 
as not having current asthma based on their 
status at the time of the examination. Children 
whose parents or guardians did not report 
wheeze or the other asthma-like symptoms or 
asthma medication use on any of the follow-up 
questionnaires were classified as nonasthmatics 
at the time of the last negative questionnaire.
Statistical analyses. Phthalate metabolite 
concentrations were right-skewed and trans-
formed using the natural logarithm (ln). 
Concentrations that were below the limit of 
detection (LOD) were assigned a value of 
0.5 × LOD. Variables assessed as potential 
confounders were selected from those known 
or suspected of being associated with phthalate 
concentrations or asthma (Just et al. 2012a; 
Miller et al. 2004; Whyatt et al. 2012). 
Variables were retained in the models if they 
were associated with the outcome (p ≤ 0.10) 
and/or addition or removal changed the coef-
ficient for the exposure (phthalate metabolite) 
to outcome relationship by > 10%. Variables 
assessed included race/ethnicity, prenatal and 
postnatal household tobacco smoke exposure, 
maternal history of asthma, maternal education, 
maternal marital status, material hardship (lack 
of food, housing, gas, or electricity, clothing, or 
medicine during pregnancy), sex of the child, 
and child age at diagnosis (age at diagnosis as 
either current asthma or not current asthma 
for children with a history of the asthma-like 
symptoms seen by the physician, or age at clas-
sification as nonasthmatic at the last negative 
questionnaire for children without history of 
the asthma-like symptoms). Maternal prenatal 
demoralization also was assessed by validated 
questionnaire (Dohrenwend et al. 1978) 
because it previously has been associated with 
wheeze among children in the cohort (Reyes 
et al. 2011). Models were also adjusted for 
maternal prenatal BPA urinary concentra-
tions (Donohue et al. 2013) but not child 
postnatal BPA concentrations because inclu-
sion caused < 10% change in the phthalate 
exposure–outcome relationship. In addition, 
we assessed whether child postnatal urinary 
phthalate concentrations acted as a confounder 
using the phthalates measured at child ages 3, 
5, and 7 years (2 children who had phthalates 
measured in urine collected at age 7 but whose 
asthma status was determined before age 7 were 
removed from the age 7 analyses). However, 
none of the postnatal phthalate metabolite 
concentrations were associated with child 
asthma (see Supplemental Material, Table S2), 
and inclusion caused < 10% change in effect 
size of predictor variables. The maternal 
phthalate urinary concentrations were included 
in models as ln-transformed variables, and also 
were categorized into tertiles and modeled 
using indicator variables to estimate relative 
risks comparing the second and third tertiles to 
the first tertile (referent). Metabolite concentra-
tions were adjusted for specific gravity before 
categorizing using the formula described previ-
ously (Hauser et al. 2004). Consistent with 
our prior approach (Just et al. 2012a), relative 
risks were estimated using Poisson regression 
with robust standard error estimation using the 
generalized estimating equations based method 
of Zou (2004) (see also Lovasi et al. 2012; 
Spiegelman and Hertzmark 2005). Analyses 
were conducted using SPSS version 21 (SPSS, 
IBM, Chicago, IL). Results were considered 
significant at p < 0.05.Prenatal phthalates and child asthma
Environmental Health Perspectives  •  volume 122 | number 10 | October 2014  1143
Results
Table 1 provides subject characteristics. Self-
reported ethnicity was African American 
(35.7%) or Domincan (64.3%). Educational 
attainment was low (35.7% had not completed 
high school), and the majority (68%) reported 
never having been married. Table 2 shows the 
distribution of the urinary phthalate metabo-
lite concentrations measured in maternal 
prenatal spot urine. All phthalate metabolites 
were detected in 100% of maternal prenatal 
urine samples except for MBzP in one 
sample (assigned a value of 0.11 ng/mL). 
Concentrations were generally comparable with 
those of a representative sample of the U.S. 
population sampled over roughly the same time 
period (1999–2004) (CDC 2009). Table 3 
shows the correlations between the (ln)maternal 
prenatal phthalate metabolite concentrations 
adjusted for specific gravity. All metabolites 
were positively correlated, with correlation 
coefficients ranging from 0.16 (for MEP and 
MnBP) to 0.50 (for MnBP and MBzP) (all 
p-values < 0.01).
A total of 1,013 repeat questionnaires on 
wheeze and other asthma-like symptoms were 
administered between ages 5 and 11 years 
(mean, 3.7 ± 1.1 questionnaires per child). 
The children were 8.1 ± 1.9 years on average 
at the time of the last questionnaire admin-
istration. Of the 300 children, 154 had a 
history of the following asthma-like symptoms 
on one or more questionnaires between 5 and 
11 years: a report in the preceding 12 months 
of wheeze or whistling in the chest, a cough 
that lasted more than a week, other breathing 
problems, and/or reported use of asthma 
rescue or controller medication. These 154 
children met our screening criteria for the 
physician diagnosis of asthma based on the 
first report of any of these symptoms. At the 
time of the physician exam, 94 children were 
diagnosed with current asthma and 60 were 
diagnosed as not having current asthma. A 
greater proportion of African-American than 
Dominican children were classified as having 
current asthma (36% vs. 29%, chi-square 
p = 0.11). The remaining 146 children had 
no history of any of the asthma-like symptoms 
on repeat questionnaires and were classi-
fied as nonasthmatic at the time of the last 
negative questionnaire.
We estimated relative risks (RRs) for 
three different outcome groups relative to the 
children classified as nonasthmatic (n = 146) 
as a common referent group: a) children with 
any report of symptoms and/or medication 
use, regardless of the outcome of their asthma 
examination (n = 154); b) children diagnosed 
with current asthma at the time of their physi-
cian examination (n = 94); and c) children with 
a history of symptoms but diagnosed as not 
having current asthma at the time of the physi-
cian examination (n = 60). Linear results are 
presented in Figures 1–3 and categorical results 
in Table 4.
Report of asthma-like symptoms regardless 
of the outcome of the asthma   examination. 
Compared with nonasthmatic children, a 
significant association was seen between 
maternal prenatal urinary MBzP and MnBP 
concentrations and children with a history of 
asthma-like symptoms: RR = 1.12 (95% CI: 
1.01, 1.24) and RR = 1.16 (95% CI: 1.02, 
1.33) per ln-unit increase, respectively 
(Figure 1). Compared with children of 
mothers with MBzP and MnBP concentra-
tions in the first tertile, the RRs for a history 
of asthma-like symptoms among those in 
the second tertile were 1.25 (95% CI: 0.94, 
1.65) and 1.39 (95% CI: 1.06, 1.82), respec-
tively, and among those in the third tertile 
the RRs were 1.39 (95% CI: 1.05, 1.86) 
and 1.44 (95% CI: 1.09, 1.90, respectively 
(Table 4). There was no significant increase 
in risk of asthma-like symptoms in the linear 
models associated with either maternal MEP 
or MEHHP concentrations (Figure 1). 
However, in the categorical models (Table 4) 
compared with children of mothers with 
MEP in the first tertile, a significant increase 
in risk of asthma-like symptoms was seen 
among those in the second tertile (RR = 1.33; 
95% CI: 1.03, 1.73) but not among those in 
the third tertile (RR = 1.08; 95% CI: 0.82, 
1.42). There was no increase in risk of asthma-
like symptoms across tertiles of MEHHP 
  concentrations (Table 4).
Diagnosis of current asthma at physician 
examination. Compared with nonasthmatic 
children, maternal prenatal MBzP and MnBP 
concentrations, but not the other phthalate 
metabolites, were associated with the diagnosis 
of the child with current asthma at the physi-
cian examination in the linear models: RR 
= 1.17 (95% CI: 1.01, 1.35) and RR = 1.25 
(95% CI: 1.04, 1.51) per ln-unit increase, 
respectively (Figure 2). In the categorical 
models (Table 4), compared with children 
of mothers with MBzP and MnBP concen-
trations in the first tertile, RRs for current 
asthma among those in the second tertile were 
1.31 (95% CI: 0.87, 1.96) and 1.87 (95% CI: 
1.28, 2.67), respectively, and among those 
in the third tertile RRs were 1.72 (95% CI: 
1.15, 2.59) and 1.78 (95% CI: 1.18, 2.70), 
respectively. There were no significant asso-
ciations between diagnosis of current asthma 
and maternal prenatal MEP or MEHHP 
concentrations in either   linear (Figure 2) or 
categorical (Table 4) models.
Table 2. Distribution of phthalate metabolites in maternal prenatal urine during pregnancy (ng/mL).
Geometric mean (95% CI)
Concentration (ng/mL)
25% 50% 75%
MEHHP 22.4 (19.4, 25.9) 10.6 21.6 50.0
MBzPa 13.5 (11.6, 15.6) 5.8 15.0 31.9
MnBP 37.5 (33.2, 42.3) 19.3 38.3 80.5
MEP 160.3 (139.6, 184.0) 68.0 143.5 335.2
aAll metabolites were above the LOD except for one sample for MBzP, which was imputed (LOD × 0.05). 
Table 3. Correlationa between prenatal phthalate 
metabolite concentrations adjusted for specific 
gravity (n = 300).
(ln)MnBP (ln)MEP (ln)MEHHP
(ln)MBzP 0.50* 0.16* 0.27*
(ln)MnBP 0.27* 0.30*
(ln)MEP 0.17*
aSpearman’s rank. *p < 0.01.
Table 1. Characteristics of children (n = 300) from the CCCEH birth cohort.
Characteristic n (%) or mean ± SD
Maternal age (years) 25.3 ± 4.8
Maternal asthma history 76 (25.3)
Maternal demoralizationa 1.1 ± 0.65
Ethnicity
African American 107 (35.7)
Dominican 193 (64.3)
Maternal education
< High school 107 (35.7)
High school or general educational development 114 (38.0)
> High school 79 (26.3)
Marital status
Never married 204 (68)
Marriedb 81 (27.0)
Separated, widowed, divorced 15 (5.0)
Household smoke exposurec 154 (51.3)
Prenatal urinary bisphenol A (ng/mL) 3.1 ± 4.3
Child age at assessment (years) 8.1 ± 1.9
Child sex (% female) 163 (54.3)
aMean of 27 items each on 5-point Likert scale (0–4) (Dohrenwend et al. 1978). bIncludes women living with the same 
partner for > 7 years. cWhether or not others smoked in the home during the prenatal period and whether or not the 
mother and/or   others smoked in the home during childhood gathered by repeat questionnaire.Whyatt et al.
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History of symptoms but diagnosis of not 
current asthma at physician   examination. 
Compared with nonasthmatic children, 
maternal prenatal MnBP concentrations 
were associated with a history of asthma-
like symptoms but diagnosis of not current 
asthma at the physician examination: RR = 
1.33 (95% CI: 1.05, 1.70) per ln-unit increase 
(Figure 3). In the categorical models (Table 4), 
compared with mothers with MnBP concentra-
tions in the first tertile, the RR for not current 
asthma for those in the second tertile was 1.46 
(95% CI: 0.81, 2.65) and in the third tertile 
was 1.71 (1.02, 2.88). The association between 
maternal prenatal MBzP concentrations and 
diagnosis of not current asthma among those 
with a history of the asthma-like symptoms 
was of borderline significance in the linear 
model: RR 1.17 (95% CI: 0.98, 1.41) per 
ln-unit increase (Figure 3). However, there was 
no increase in risk across tertiles of maternal 
MBzP concentration, and there were no 
significant associations between diagnosis of 
not current asthma and maternal prenatal MEP 
or MEHHP concentrations in either linear 
(Figure 3) or categorical (Table 4) models.
Discussion
We observed a significant association between 
concentrations of MBzP, the BBzP metabolite, 
and MnBP, the DnBP metabolite, in maternal 
urine collected during the third trimester of 
pregnancy and diagnosis of current asthma 
among CCCEH cohort children 5–11 years of 
age. Risk of current asthma was > 70% higher 
among children whose mothers had BBzP 
and DnBP metabolite concentrations during 
pregnancy in the third versus first tertile. This 
work extends our previous CCCEH findings in 
cross-sectional analyses that increases in concen-
trations of metabolites of BBzP, as well as DEP, 
in child urine were associated with increases 
in FeNO, an indicator of airway inflamma-
tion and asthma (Just et al. 2012a). Although 
prior research has shown associations between 
other phthalates and child asthma, only one 
prior cross-sectional study reported evidence of 
a dose–response relationship between MBzP 
and child asthma but was limited by small 
sample size (n = 101) (Hsu et al. 2012). Other 
cross-sectional studies in Sweden (n = 400 
children ages 3–8 years) and Bulgaria (n = 102 
children ages 2–7 years) have reported asso-
ciations between house dust concentrations of 
DEHP and child asthma, and of BBzP and 
child eczema and rhinitis, but not BBzP and 
child asthma (Bornehag et al. 2004; Kolarik 
et al. 2008). A recent cross-sectional study 
reported a significant association between child 
asthma and mono(carboxyoctyl) phthalate and 
mono(carboxynonyl) phthalate in first morning 
void urine collected from 623 10-year-old 
Norwegian children, but did not observe 
any association between asthma and urinary 
concentrations of the BBzP or DnBP metabo-
lites (Bertelsen et al. 2013). Another recent 
Figure 1. Association between maternal prenatal 
(ln)phthalate metabolite concentrations and 
presence (n = 154) compared with the absence 
(n = 146) of a history of asthma-like symptoms on 
repeat questionnaires administered between child 
ages 5 and 11 years. RRs were estimated using 
Poisson regression with robust standard error 
estimation using the generalized estimating equa-
tions controlling for maternal asthma, household 
tobacco smoke exposure, maternal prenatal BPA, 
maternal prenatal demoralization, and maternal 
prenatal specific gravity. 
*p < 0.05.
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Figure 2. Association between maternal   prenatal 
(ln)phthalate metabolite concentrations and 
diagnosis of current asthma (n = 94) compared 
with nonasthmatic (n = 146) between child ages 5 
and 11 years. RRs were estimated using Poisson 
regression with robust standard error estimation 
using the generalized estimating equations control-
ling for maternal asthma, household tobacco 
smoke exposure, maternal prenatal BPA, maternal 
prenatal demoralization, child age, and maternal 
prenatal specific gravity. 
*p < 0.05.
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Figure 3. Association between maternal prenatal (ln)
phthalate metabolites concentrations and diagnosis 
as not current asthma among children with a history 
of the asthma-like symptoms (n = 60) compared 
with children without any history of asthma-like 
symptoms classified as nonasthmatics (n = 146). RRs 
were estimated using Poisson regression with robust 
standard error estimation using the generalized esti-
mating equations controlling for maternal asthma, 
household tobacco smoke exposure, maternal 
prenatal BPA, maternal prenatal demoralization, 
child age, and maternal prenatal specific gravity. 
*p < 0.05. 
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Table 4. RR (95% CI) for history of asthma-like symptoms (group 1, n = 154), diagnosis of current asthma (group 2, n = 94), and diagnosis of not current asthma 
(group 3, n = 60) compared with nonasthmatics (n = 146) by tertiles of phthalate metabolites.
Outcome group 
and exposure
MBzP MnBP MEP MEHHP
Case/control (n) RR (95% CI) Case/control (n) RR (95% CI) Case/control (n) RR (95% CI) Case/control (n) RR (95% CI)
Group 1
1st tertile 44/57 Referent 46/60 Referent 46/52 Referent 57/47 Referent
2nd tertile 55/47 1.25 (0.94, 1.65) 53/41 1.39 (1.06, 1.82)* 59/42 1.33 (1.03, 1.73)* 46/47 0.92 (0.71, 1.20)
3rd tertile 55/42 1.39 (1.05, 1.86)* 55/45 1.44 (1.09, 1.90)* 49/52 1.08 (0.82, 1.42) 51/52 0.97 (0.74, 1.28)
Group 2
1st tertile 25/57 Referent 27/60 Referent 29/52 Referent 34/47 Referent
2nd tertile 34/47 1.31 (0.87, 1.98) 38/41 1.87 (1.28, 2.67)** 35/42 1.11 (0.97, 1.27) 27/47 0.98 (0.85, 1.12)
3rd tertile 35/42 1.72 (1.15, 2.59)** 29/45 1.78 (1.18, 2.70)** 30/52 1.04 (0.91, 1.19) 33/52 1.03 (0.89, 1.20)
Group 3
1st tertile 19/57 Referent 19/60 Referent 17/52 Referent 23/47 Referent
2nd tertile 21/47 1.34 (0.80, 2.25) 15/41 1.46 (0.81, 2.65) 24/42 1.15 (0.99, 1.34) 19/47 0.98 (0.84, 1.13)
3rd tertile 20/42 1.44 (0.83, 2.49) 26/45 1.71 (1.02, 2.88)* 19/52 1.04 (0.91, 1.89) 18/52 0.95 (0.82, 1.10)
Models compare children in each outcome group with children without history of asthma-like symptoms controlling for maternal asthma, household smoke exposure,   maternal 
prenatal BPA, maternal prenatal demoralization, maternal prenatal specific gravity, and child age (for outcome groups 2 and 3).
*p < 0.05. **< 0.01.Prenatal phthalates and child asthma
Environmental Health Perspectives  •  volume 122 | number 10 | October 2014  1145
cross-sectional study conducted among partici-
pants in NHANES (National Health and 
Nutrition Examination Study) found urinary 
concentrations of MBzP, but not MnBP, to 
be significantly associated with current asthma, 
wheeze, hay fever, and rhinitis in adults 
(n = 1,546) but not in children 6–17 years of 
age (n = 779) (Hoppin et al. 2013).
Consistent with our prior findings (Whyatt 
et al. 2012), significant correlations were seen 
between prenatal urinary concentrations of 
MBzP and MnBP adjusted for specific gravity 
(Spearman’s rho = 0.50). This may reflect 
common sources of exposure and/or similar 
metabolic pathways. Consumer products 
including personal care products and home 
materials are sources of exposure to both 
of these phthalates (Buckley et al. 2012; 
Carlstedt et al. 2013). In addition, MnBP is 
a minor metabolite of BBzP, accounting for 
approximately 6% (Anderson et al. 2001). 
Nonetheless, most MnBP in urine is attrib-
utable to DnBP exposures. Several studies, 
including findings in the CCCEH cohort, 
suggest that PVC materials in the home are 
likely a substantial source of BBzP exposure, 
as indicated by measures in maternal and 
child urine and residential and personal air 
samples (Adibi et al. 2008; Carlstedt et al. 
2013). Although DEHP is also a constituent 
of PVC, evidence suggests that exposure to 
this phthalate occurs primarily through the 
diet, likely as a result of use in food pack-
aging (Koch 2013; Rudel et al. 2011). Prior 
cross-sectional studies also have found PVC 
materials in the home to be associated with 
child asthma and other respiratory symptoms 
(Bornehag and Nanberg 2010), and these 
results provide at least some corroboration 
for the current findings. For example, in a 
prospective study of 4,779 children in Sweden 
without asthma or respiratory symptoms at 
child ages 1–3 years, PVC flooring at baseline 
was associated with parental report of child 
asthma at the 5- and 10-year follow-up 
(Larsson et al. 2010; Shu et al. 2014).
The significant association seen in our 
present study between MnBP and MBzP 
urinary concentrations and asthma-like 
symptoms, regardless of whether or not the 
child received a diagnosis of current asthma, 
was not anticipated. These findings may imply 
that prenatal exposure to some phthalates has 
effects on transient wheeze and/or nonspe-
cific airway hyperresponsiveness. It is possible 
that the respiratory consequences of prenatal 
exposure to phthalates mimic what has been 
observed following prenatal exposure to ciga-
rette smoke, where several large cohort studies 
have essentially established its role in recurrent 
wheeze in very young children (Magnusson 
et al. 2005). Alternatively, prenatal phthalate 
exposure may induce a nonspecific airway 
hyperresponsiveness, manifested as report of 
wheeze, use of asthma medication, cough, or 
other breathing problems, that develops into 
clinical asthma during childhood only in a 
subset of children. The development of airway 
hyperresponsiveness is believed to have an 
environmental component (Lund et al. 2007; 
Riley et al. 2012), and develops at a very early 
age (Lesouef et al. 1989). Further prospective 
studies are needed to resolve these important 
clinical questions.
Research on mechanisms whereby phthal-
ates might induce asthma or asthma-like 
symptoms is extremely limited [reviewed by 
(Kwak et al. 2009)]. Several phthalates have 
shown adjuvant effects on proallergic T helper 
2 differentiation and immunoglobulin (Ig) 
G1 and IgE production when administered 
via subcutaneous or intraperitoneal injection 
to BALB/c mice sensitized by ovalbumin 
(Bornehag and Nanberg 2010; Guo et al. 
2012). Our prior research in the CCCEH 
cohort did not find any association between 
maternal prenatal urinary MBzP concentrations 
and child seroatopy, although we did observe 
an association between maternal prenatal 
MBzP concentrations and early-onset eczema 
(Just et al. 2012b). In addition, as discussed 
above, when we used a repeated-measures 
design, we saw a significant association between 
MBzP concentrations in child urine and 
FeNO, suggesting that MBzP induces airway 
inflammation (Just et al. 2012a). In cross-
sectional analyses, urinary concentrations of 
MBzP also have been shown to be associated 
with C-reactive protein, a nonspecific marker 
of systemic inflammation, and both MBzP and 
MnBP have been associated with biomarkers of 
oxidative stress (Ferguson et al. 2011, 2012). 
However, the relevance of these findings to the 
potential effect of the phthalates on respira-
tory health remains unclear. Mechanistic data 
explaining why the prenatal period of exposure 
may be deleterious also are limited, but our 
group has provided evidence of epigenetic regu-
lation following prenatal exposure to several 
environmental exposures in human and mouse 
studies on asthma (Kundakovic 2013; Liu et al. 
2008; Niedzwiecki et al. 2012; Perera et al. 
2009; Tang et al. 2012).
Strengths of the current study include 
the standardized physician diagnosis of child 
asthma that is an improvement over most prior 
research, which used parental report of child 
asthma as the outcome. Additionally, this is 
the first study to evaluate associations between 
prenatal phthalate exposure and asthma during 
early to mid-childhood in a longitudinal birth 
cohort. This is a strength because most prior 
studies of phthalates and asthma have been 
cross-sectional. The rate of both maternal and 
child asthma in our cohort is high (31.8% 
and 25.2%, respectively). Asthma prevalence 
among New York City children ranges from 
3% to 25% (Nicholas et al. 2005), with some 
inner-city communities having triple the 
asthma prevalence of their bordering neigh-
borhoods. Although family history of asthma 
or atopy were not required inclusion criteria 
for the current cohort, pregnant mothers were 
informed at enrollment that the research was 
evaluating environmental risk factors in child 
asthma development, and this may have been 
an incentive for mothers whose children were 
at higher risk to participate.
Limitations also should be noted. We used 
as our exposure dosimeters the measurements 
of the phthalate metabolite concentrations in 
a single prenatal spot urine sample, and this 
could result in exposure misclassification, 
especially for some phthalate metabolites. 
Controlling for urinary dilution, we previously 
reported that the ICCs for phthalate metabo-
lites in repeat prenatal spot urine samples 
(n = 135) collected biweekly over the last 
6 weeks of pregnancy from 48 women in the 
CCCEH cohort were 0.77 for MBzP, 0.64 
for MnBP, 0.27 for MEHHP, and 0.19 for 
MEP (Whyatt et al. 2012), indicating that 
reliability of the phthalate biomarkers differs 
across the phthalates. We would expect the 
exposure misclassification for these phthalates 
to be nondifferential with respect to asthma 
and could thus reduce our power to observe 
an effect for either MEP or MEHHP on 
asthma risk, because they had the lower ICCs. 
However, this is less likely to be a problem 
with MBzP and MnBP due to the higher ICCs 
in repeat prenatal urine samples, coupled with 
the relatively high correlations seen previ-
ously in the CCCEH cohort between BBzP 
concentrations in maternal 48-hr prenatal 
personal air samples and 2-week integrated 
indoor air samples (Spearman’s rho = 0.67) 
and between BBzP in maternal personal and 
indoor air samples and MBzP concentra-
tions in maternal prenatal urine (Spearman’s 
rho = 0.48 and 0.71, respectively) (Adibi et al. 
2008). However, the correlations between 
DnBP concentration in maternal prenatal 
personal and indoor air samples and MnBP 
concentrations in maternal prenatal urine were 
considerably lower (Spearman’s rho = 0.05 and 
0.27, respectively) (Adibi et al. 2008). Missing 
data and loss to follow-up, as often occurs in 
a long-term prospective study, could also bias 
study results (Kurukulaaratchy et al. 2003; 
Matricardi et al. 2008). However, 97% of the 
children in the current study had questionnaire 
data on ISAAC wheeze and other respiratory 
symptoms collected at least twice, and 86% of 
the children had questionnaire data collected 
three or more times. In addition, maternal 
urine samples were collected during the third 
trimester of pregnancy, and this is another 
potential limitation given that the critical 
window of susceptibility is not known but 
may well be earlier in pregnancy. Additionally, 
the research was conducted in an inner-city Whyatt et al.
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cohort, with high rates of maternal and child 
asthma and was restricted to nonsmoking 
mothers during pregnancy. Therefore, results 
may well not be generalizable to other popula-
tions. Further, noncausal associations (e.g., due 
to confounding by some other factor associ-
ated with phthalates and asthma) cannot be 
ruled out. For all of these reasons, the findings 
should be interpreted with caution before 
replication in other cohorts that include evalu-
ation of associations between child asthma and 
exposures during other trimesters of pregnancy.
Conclusion
These results suggest that prenatal exposure to 
BBzP and DnBP may increase risk of child-
hood asthma. The findings raise new concerns 
that the presence of relatively ubiquitous 
environmental exposures may have deleterious 
respiratory effects. However, because, to our 
knowledge, this is the first study to evaluate 
associations between prenatal phthalate 
exposures and child asthma risk, results 
require replication.
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